Trends in GPCR drug discovery: New agents, targets and indications

Nature Reviews Drug Discovery

Volumn 16, Issue 12, 2017, Pages 829-842

  Hauser, Alexander S ^a   Attwood, Misty M ^b   Rask Andersen, Mathias ^b   Schiöth, Helgi B ^b   Gloriam, David E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABALOPARATIDE; AM 152; APELIN; ARIPIPRAZOLE LAUROXIL; AVACOPAN; AZD 4901; AZP 531; BNC 101; BREXPIPRAZOLE; CAMICINAL; CANGRELOR; CARIPRAZINE; DROXIDOPA; DULAGLUTIDE; ELUXADOLINE; ERENUMAB; ETELCALCETIDE; FLIBANSERIN; G PROTEIN COUPLED RECEPTOR; GLPG 0974; GLPG 1205; GWP 42003; GWP 42006; HOMATROPINE METHYL BROMIDE PLUS HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE; INT 767; LIXISENATIDE; LJPC 501; MLE 4901; NALDEMEDINE; NALOXEGOL; NETUPITANT; NETUPITANT PLUS PALONOSETRON; OLODATEROL; PA 101B; PARATHYROID HORMONE; PB 1046; PIMAVANSERIN; RECOMBINANT PARATHYROID HORMONE[1-84]; ROLAPITANT; RX 10045; SELEXIPAG; SETMELANOTIDE; SONIDEGIB; SUVOREXANT; SYMPROIC; TASIMELTEON; TXA 127; UBROGEPANT; UNINDEXED DRUG; VORAPAXAR; VSN 16R;

ARTICLE; BASAL CELL CARCINOMA; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DEPRESSION; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERPARATHYROIDISM; HYPOACTIVE SEXUAL DESIRE DISORDER; HYPOPARATHYROIDISM; INSOMNIA; IRRITABLE COLON; MIGRAINE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; PULMONARY HYPERTENSION; SCHIZOPHRENIA; SLEEP DISORDER; STOMACH PARESIS; ALLOSTERISM; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; TRENDS;

ALLOSTERIC REGULATION; ANIMALS; DRUG APPROVAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85035315619     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2017.178     Document Type: Article

References (99)

1. Rask-Andersen, M., Masuram, S. & Schiöth, H. B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9-26 (2014).
2. The IDG Knowledge Management Center. Unexplored opportunities in the druggable human genome. Nat. Rev. Drug Disc. http: //www. nature. com/nrd/posters/ druggablegenome/nrd-druggablegenome. pdf (2016).
3. Kolakowski, L. F. Jr. GPCRDb: a G-protein-coupled receptor database. Recept. Channels 2, 1-7 (1994).
4. Schiöth, H. B. & Fredriksson, R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen. Comp. Endocrinol. 142, 94-101 (2005).
5. Southan, C. et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: Towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res. 44, D1054-D1068 (2016).
6. Christopoulos, A. et al. International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol. Rev. 66, 918-947 (2014).
7. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
8. Violin, J. D., Crombie, A. L., Soergel, D. G. & Lark, M. W. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci. 35, 308-316 (2014).
9. de Graaf, C. et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev. 68, 954-1013 (2016).
10. Solari, R., Pease, J. E. & Begg, M. Chemokine receptors as therapeutic targets: why aren't there more drugs Eur. J. Pharmacol. 746, 363-367 (2015).
11. Nicoletti, F., Bruno, V., Ngomba, R. T., Gradini, R. & Battaglia, G. Metabotropic glutamate receptors as drug targets: what's new Curr. Opin. Pharmacol. 20, 89-94 (2015).
12. Du, C. & Xie, X. G protein-coupled receptors as therapeutic targets for multiple sclerosis. Cell Res. 22, 1108-1128 (2012).
13. Bar-Shavit, R. et al. G protein-coupled receptors in cancer. Int. J. Mol. Sci. 17, 1320 (2016).
14. Lappano, R. & Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47-60 (2011).
15. Cromie, K. D., Van Heeke, G. & Boutton, C. Nanobodies and their use in GPCR drug discovery. Curr. Top. Med. Chem. 15, 2543-2557 (2015).
16. Zhang, R. & Xie, X. Tools for GPCR drug discovery. Acta Pharmacol. Sin. 33, 372-384 (2012).
17. Jacobson, K. A. New paradigms in GPCR drug discovery. Biochem. Pharmacol. 98, 541-555 (2015).
18. Wootten, D., Miller, L. J., Koole, C., Christopoulos, A. & Sexton, P. M. Allostery and biased agonism at class B G protein-coupled receptors. Chem. Rev. 117, 111-138 (2017).
19. Wootten, D., Christopoulos, A. & Sexton, P. M. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat. Rev. Drug Discov. 12, 630-644 (2013).
20. Pupo, A. S. et al. Recent updates on GPCR biased agonism. Pharmacol. Res. 112, 49-57 (2016).
21. Isberg, V. et al. GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res. 44, D356-D364 (2016).
22. Law, V. et al. DrugBank 4. 0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2014).
23. Ahlgren, N. A., Ren, J., Lu, Y. Y., Fuhrman, J. A. & Sun, F. Alignment-free d2 oligonucleotide frequency dissimilarity measure improves prediction of hosts from metagenomically-derived viral sequences. Nucleic Acids Res. 45, 39-53 (2017).
24. Koscielny, G. et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 45, D985-D994 (2016).
25. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there Nat. Rev. Drug Discov. 5, 993-996 (2006).
26. Rask-Andersen, M., Almén, M. S. & Schiöth, H. B. Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590 (2011).
27. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Disc. 16, 19-34 (2017).
28. Miller, P. D. et al. Effect of abaloparatide versus placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA 316, 722-733 (2016).
29. Kaku, K., Enya, K., Nakaya, R., Ohira, T. & Matsuno, R. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes. Metab. 17, 675-681 (2015).
30. Mullard, A. 2016 FDA drug approvals. Nat. Rev. Drug Discov. 16, 73-76 (2017).
31. Hutchings, C. J., Koglin, M., Olson, W. C. & Marshall, F. H. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat. Rev. Drug Discov. 16, 1-24 (2017).
32. Oh, D. Y. & Olefsky, J. M. G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat. Rev. Drug Discov. 15, 161-172 (2016).
33. Khanna, A. et al. Angiotensin II for the treatment of vasodilatory Shock. N. Engl. J. Med. 377, 419-430 (2017).
34. Mancini, A. D. & Poitout, V. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes. Obes. Metab. 17, 622-629 (2015).
35. Gao, Z. G. & Jacobson, K. A. Allosteric modulation and functional selectivity of G protein-coupled receptors. Drug Discov. Today Technol. 10, e237-e243 (2013).
36. Shen, Q. et al. ASD v3. 0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res. 44, D527-D535 (2016).
37. Nickols, H. H. & Conn, J. P. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis. 61, 55-71 (2014).
38. Anighoro, A., Bajorath, J. & Rastelli, G. Polypharmacology: challenges and opportunities in drug discovery. J. Med. Chem. 57, 7874-7887 (2014).
39. Butini, S. et al. Polypharmacology of dopamine receptor ligands. Prog. Neurobiol. 142, 68-103 (2016).
40. Uhlen, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
41. Regard, J. B., Sato, I. T. & Coughlin, S. R. Anatomical profiling of G protein-coupled receptor expression. Cell 135, 561-571 (2008).
42. Komatsu, H Novel therapeutic GPCRs for psychiatric disorders. Int. J. Mol. Sci. 16, 14109-14121 (2015).
43. Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 (2010).
44. Radick, L. & Mehr, S. R. The latest innovations in the drug pipeline for multiple sclerosis. Am. Health Drug Benefits 8, 448-453 (2015).
45. Zettl, U. K., Rommer, P., Hipp, P. & Patejdl, R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther. Adv. Neurol. Disord. 9, 9-30 (2016).
46. Thathiah, A. & De Strooper, B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 12, 73-87 (2011).
47. Bowen, R. L., Perry, G., Xiong, C., Smith, M. A. & Atwood, C. S. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J. Alzheimers Dis. 44, 549-560 (2015).
48. Ferrero, H., Solas, M., Francis, P. T., & Ramirez, M. J. Serotonin 5-HT6 receptor antagonists in Alzheimer's disease: therapeutic rationale and current development status. CNS Drugs 31, 19-32 (2017).
49. Dowie, M. J., Scotter, E. L., Molinari, E. & Glass, M. The therapeutic potential of G-protein coupled receptors in Huntington's disease. Pharmacol. Ther. 128, 305-323 (2010).
50. Veenstra-VanderWeele, J. et al. Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology 42, 1390-1398 (2017).
51. Hampp, C., Borders-Hemphill, V., Moeny, D. G. & Wysowski, D. K. Use of antidiabetic drugs in the U. S., 2003-2012. Diabetes Care 37, 1367-1374 (2014).
52. International Diabetes Federation. IDF Diabetes Atlas Sixth Ed. IDF https: //www. idf. org/e-library/ epidemiology-research/diabetes-atlas/19-atlas-6th-edition. html (2013).
53. Olokoba, A. B., Obateru, O. A. & Olokoba, L. B. Type 2 diabetes mellitus: a review of current trends. Oman Med. J. 27, 269-273 (2012).
54. Nauck, M. A. et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39, 231-241 (2016).
55. Kolar, G. R., Grote, S. M. & Yosten, G. L. C. Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. J. Intern. Med. 281, 25-40 (2017).
56. Lauffer, L., Iakoubov, R. & Brubaker, P. L. GPR119: 'double-dipping' for better glycemic control. Endocrinology 149, 2035-2037 (2008).
57. Ritter, K., Buning, C., Halland, N., Perlein, C. & Schwink, L. G. Protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J. Med. Chem. 59, 3579-3592 (2016).
58. Lopez Vicchi, F. et al. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol. Res. 109, 74-80 (2016).
59. Lynch, J. & Wang, J. G. Protein-coupled receptor signaling in stem cells and cancer. Int. J. Mol. Sci. 17, 707 (2016).
60. Li, S., Huang, S. & Peng, S. B. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol. 27, 1329-1339 (2005).
61. Moreno, E. et al. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J. Biol. Chem. 289, 21960-21972 (2014).
62. Nosengo, N. Can you teach old drugs new tricks Nature 534, 314-316 (2016).
63. Reinscheid, R. K. in Handbook of Biologically Active Peptides (ed. Kastin, A.) 869-874 (Academic Press, 2013).
64. Halls, M. L., Bathgate, R. A. D., Sutton, S. W., Dschietzig, T. B. & Summers, R. J. International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol. Rev. 67, 389-440 (2015).
65. Prevete, N., Liotti, F., Marone, G., Melillo, R. M. & De Paulis, A. Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacol. Res. 102, 184-191 (2015).
66. Ramos-lvarez, I. et al. Insights into bombesin receptors and ligands: highlighting recent advances. Peptides 72, 128-144 (2015).
67. Yamada, K., Wada, E. & Wada, K. Bombesin-like peptides studies on food intake and social behaviour with receptor knock-out mice. Ann. Med. 32, 519-529 (2000).
68. Lang, R. et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol. Rev. 67, 118-175 (2015).
69. Freimann, K., Kurrikoff, K. & Langel, Galanin receptors as a potential target for neurological disease. Expert Opin. Ther. Targets 19, 1665-1676 (2015).
70. Wlodawer, A. & Vondrasek, J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27, 249-284 (1998).
71. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502 (2002).
72. Varghese, J N. Development of neuraminidase inhibitors as anti-influenza virus drugs. Drug Dev. Res. 46, 176-196 (1999).
73. Piscitelli, C. L., Kean, J., de Graaf, C. & Deupi, X. A. Molecular pharmacologist's guide to G protein-coupled receptor crystallography. Mol. Pharmacol. 88, 536-551 (2015).
74. Jazayeri, A., Dias, J. M. & Marshall, F. H. From G protein-coupled receptor structure resolution to rational drug design. J. Biol. Chem. 290, 19489-19495 (2015).
75. Cooke, R. M., Brown, A. J. H., Marshall, F. H. & Mason, J. S. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov. Today 20, 1355-1364 (2015).
76. Tautermann, C. S. & Gloriam, D. E. Editorial overview: new technologies: GPCR drug design and function-exploiting the current (of) structures. Curr. Opin. Pharmacol. 30, vii-x (2016).
77. Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185-190 (2016).
78. Sakmar, T. P. & Huber, T. Pharmacology: inside-out receptor inhibition. Nature 540, 344-345 (2016).
79. Jazayeri, A., Andrews, S. P. & Marshall, F. H. Structurally enabled discovery of adenosine A2A receptor antagonists. Chem. Rev. 117, 21-37 (2017).
80. Marinissen, M. J. & Gutkind, J. S. G-Protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22, 368-376 (2001).
81. Neves, S. R., Ram, P. T. & Iyengar, R. G protein pathways. Science 296, 1636-1639 (2002).
82. Ludwig, A., Belfiore, N. M., Pitra, C., Svirsky, V. & Jenneckens, I. Genome duplication events and functional reduction of ploidy levels in sturgeon (Acipenser, Huso and Scaphirhynchus). Genetics 158, 1203-1215 (2001).
83. Masuho, I. et al. Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors. Sci. Signal. 8, ra123 (2015).
84. Costa-Neto, C. M., Parreiras-e-Silva, L. T. & Bouvier, M. A pluridimensional view of biased agonism. Mol. Pharmacol. 90 587-595 (2016).
85. Nygaard, R. et al. The dynamic process of 2-adrenergic receptor activation. Cell 152, 532-542 (2013).
86. Viscusi, E. R. et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the opioid receptor, for the intravenous treatment of acute pain. Pain 157, 264-272 (2016).
87. Bohn, L. M. Enhanced morphine analgesia in mice lacking arrestin 2. Science 286, 2495-2498 (1999).
88. Ikeda, Y., Kumagai, H., Motozawa, Y., Suzuki, J.-I. & Komuro, I. Biased agonism of the angiotensin II type I receptor. Int. Heart J. 56, 485-488 (2015).
89. Khoury, E., Clent, S. & Laporte, S. A. Allosteric and biased G protein-coupled receptor signaling regulation: potentials for new therapeutics. Front. Endocrinol. 5, 68 (2014).
90. Beaulieu, J. M. In vivo veritas, the next frontier for functionally selective GPCR ligands. Methods 92, 64-71 (2016).
91. Psichas, A., Reimann, F. & Gribble, F. M. Gut chemosensing mechanisms. J. Clin. Invest. 125, 908-917 (2015).
92. Cohen, L. J., Esterhazy, D., Kim, S. H., Lemetre, C., Aguilar, R. R. et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549 48-53 (2017).
93. Richards, J. L., Yap, Y. A., McLeod, K. H., Mackay, C. R. & Marino, E. Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin. Transl Immunol. 5, e82 (2016).
94. Bufe, B. et al. Recognition of bacterial signal peptides by mammalian formyl peptide receptors. J. Biol. Chem. 290, 7369-7387 (2015).
95. Foster, S. R., Roura, E. & Thomas, W. G. Extrasensory perception: odorant and taste receptors beyond the nose and mouth. Pharmacol. Ther. 142, 41-61 (2014).
96. Hamann, J. et al. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein-Coupled Receptors. Pharmacol. Rev. 67, 338-367 (2015).
97. Wacker, D. et al. How ligands illuminate GPCR molecular pharmacology. Cell 170, 414-427 (2017).
98. Ahn, S. et al. Allosteric 'beta-blocker' isolated from a DNA-encoded small molecule library. Proc. Natl Acad. Sci. USA 114, 1708-1713 (2017).
99. Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A. & Corn, J. E. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat. Rev. Drug Discov. 16, 89-100 (2017).